SSA
RCUS icon

Schonfeld Strategic Advisors’s Arcus Biosciences RCUS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.18M Buy
193,561
+96,278
+99% +$2.08M 0.03% 549
2025
Q4 		$2.32M Buy
97,283
+48,389
+99% +$987K 0.01% 820
2025
Q3 		$665K Sell
48,894
-5,034
-9% -$52.3K ﹤0.01% 1560
2025
Q2 		$439K Sell
53,928
-82,560
-60% -$705K ﹤0.01% 1588
2025
Q1 		$1.07M Buy
136,488
+1,491
+1% +$17.3K 0.01% 1262
2024
Q4 		$2.01M Sell
134,997
-538,841
-80% -$8.8M 0.01% 827
2024
Q3 		$10.3M Buy
673,838
+441,044
+189% +$6.95M 0.07% 295
2024
Q2 		$3.55M Buy
232,794
+128,934
+124% +$2.08M 0.02% 671
2024
Q1 		$1.96M Sell
103,860
-126,960
-55% -$2.2M 0.01% 999
2023
Q4 		$4.41M Buy
230,820
+87,920
+62% +$1.41M 0.03% 550
2023
Q3 		$2.57M Sell
142,900
-40,124
-22% -$806K 0.02% 746
2023
Q2 		$3.72M Sell
183,024
-110,786
-38% -$2.11M 0.03% 571
2023
Q1 		$5.36M Buy
293,810
+139,471
+90% +$2.67M 0.05% 427
2022
Q4 		$3.19M Buy
154,339
+23,711
+18% +$652K 0.03% 640
2022
Q3 		$3.42M Sell
130,628
-34,960
-21% -$925K 0.03% 665
2022
Q2 		$4.2M Buy
+165,588
New +$4.06M 0.04% 522
2022
Q1 		– Sell
-24,900
Closed -$1.01M – 2869
2021
Q4 		$1.01M Buy
24,900
+500
+2% +$19.4K 0.01% 941
2021
Q3 		$851K Buy
+24,400
New +$759K 0.01% 1023
2021
Q2 		– Sell
-50,701
Closed -$1.42M – 2241
2021
Q1 		$1.42M Buy
50,701
+35,076
+224% +$1.22M 0.02% 770
2020
Q4 		$406K Buy
+15,625
New +$378K 0.01% 1108

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Schonfeld Strategic Advisors's RCUS Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its Arcus Biosciences (RCUS) stake by 99% in Q1 2026, buying an estimated $2.08M and bringing the position to 193,561 shares worth $4.18M. The position accounts for 0.03% of the portfolio, ranked #549.

Schonfeld Strategic Advisors first reported a position in RCUS in Q4 2020 and has held it in 20 quarters since. The position peaked at $10.3M in Q3 2024. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Schonfeld Strategic Advisors held 193,561 shares of Arcus Biosciences worth $4.18M as of Q1 2026.
  • Schonfeld Strategic Advisors bought 96,278 Arcus Biosciences shares in Q1 2026, an estimated $2.08M.
  • Arcus Biosciences made up 0.03% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #549 holding.
  • Schonfeld Strategic Advisors first reported a position in Arcus Biosciences in Q4 2020 and has held it in 20 quarters since.
  • Schonfeld Strategic Advisors's Arcus Biosciences position peaked at $10.3M in Q3 2024.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.